Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum -- Life Sciences: R2 Secures 600‑System Commitment in China -- Spectrum: Recent network launches set to deliver benefits beginning in 2026 - NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter and full year ended December 31, 2025. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31, 2025 2024 Increase / (Decrease) 2025 2024 Increase / (Decrease)Revenue$382.7 $236.6 61.7% $1,246.0 $1,107.1 12.5%Net loss attributab
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the fourth quarter and full year 2025 on Thursday, March 26, 2026, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please
MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that MediBeacon Inc. ("MediBeacon"), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of
10-K - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4/A - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
SC 13G/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum -- Life Sciences: R2 Secures 600‑System Commitment in China -- Spectrum: Recent network launches set to deliver benefits beginning in 2026 - NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter and full year ended December 31, 2025. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31, 2025 2024 Increase / (Decrease) 2025 2024 Increase / (Decrease)Revenue$382.7 $236.6 61.7% $1,246.0 $1,107.1 12.5%Net loss attributab
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the fourth quarter and full year 2025 on Thursday, March 26, 2026, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that DBM Global Inc. ("DBMG"), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5 million, or $1.30 per share, on February 24, 2026 to DBMG's stockholders of record at the close of business on February 9, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $4.6 million of the total $5 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend. About INNOVATEINNOVATE Corp. is a portfoli
MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed ST. LOUIS, May 16, 2023 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced the appointment of Dr. Steve Miller as chief medical officer. In this role, Dr. Miller will be focused on driving a range of clinical and strategic initiatives. Dr. Miller formerly served as executive vice president and chief clinical officer at Cigna, where he led the company's clinical policy, quality, and per
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the company's headquarters in Somerset, New Jersey, head up the company's Legal Leadership Team, and serve on its Executive Leadership Team, reporting directly to Catalent's Executive Vice President and Chief Administrative Officer, Steven Fasman. This press release features multimedia. View the full release here: https:/
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE), today announced the appointment of Amy Wilkinson to fill the remaining vacancy on the INNOVATE Board of Directors. "Amy brings a unique blend of management expertise and global business and policy experience, and we are confident she will help guide us in our mission to drive shareholder value across our Infrastructure, Life Sciences and Spectrum operating segments," said Avie Glazer, Chairman of INNOVATE. "Amy's leadership and strategy consulting experience advising Fortune 500 companies will be a valuable addition to our Board," said Wayne Barr, Jr., Chief Executive Officer of INNOVATE